Atrasentan
Atrasentan is a small molecule pharmaceutical. It is currently being investigated in clinical studies. The pharmaceutical is active against endothelin-1 receptor. In addition, it is known to target endothelin receptor type B.
Download report
Favorite
Searched
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
No data
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
20 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Prostatic neoplasms | D011471 | C61 | — | 3 | 5 | — | — | 7 | |
| Diabetic nephropathies | D003928 | EFO_0000401 | — | 5 | 1 | — | — | 6 | |
| Iga glomerulonephritis | D005922 | EFO_0004194 | — | 1 | 1 | — | — | 2 | |
| Neoplasms | D009369 | C80 | — | — | 1 | — | — | 1 | |
| Adenocarcinoma | D000230 | — | 1 | 1 | — | — | 1 |
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Chronic renal insufficiency | D051436 | N18 | — | 4 | — | — | — | 4 | |
| Ovarian neoplasms | D010051 | EFO_0003893 | C56 | — | 1 | — | — | — | 1 |
| Fallopian tube neoplasms | D005185 | — | 1 | — | — | — | 1 | ||
| Focal segmental glomerulosclerosis | D005923 | EFO_0004236 | — | 1 | — | — | — | 1 | |
| Hereditary nephritis | D009394 | EFO_0004128 | Q87.81 | — | 1 | — | — | — | 1 |
| Kidney neoplasms | D007680 | EFO_0003865 | C64 | — | 1 | — | — | — | 1 |
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Central nervous system neoplasms | D016543 | 1 | — | — | — | — | 1 |
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | ATRASENTAN |
| INN | atrasentan |
| Description | Atrasentan is a member of pyrrolidines. |
| Classification | Small molecule |
| Drug class | endothelin receptor antagonists |
| Image (chem structure or protein) | |
| Structure (InChI/SMILES or Protein Sequence) | CCCCN(CCCC)C(=O)CN1C[C@H](c2ccc3c(c2)OCO3)[C@@H](C(=O)O)[C@@H]1c1ccc(OC)cc1 |
Identifiers
| PDB | — |
| CAS-ID | 173937-91-2 |
| RxCUI | 282355 |
| ChEMBL ID | CHEMBL9194 |
| ChEBI ID | — |
| PubChem CID | 159594 |
| DrugBank | DB06199 |
| UNII ID | V6D7VK2215 (ChemIDplus, GSRS) |
Target
Agency Approved
EDNRA
EDNRA
Organism
Homo sapiens
Gene name
EDNRA
Gene synonyms
ETA, ETRA
NCBI Gene ID
Protein name
endothelin-1 receptor
Protein synonyms
endothelin receptor subtype A, Endothelin receptor type A, endothelin-1-specific receptor, ET-A, ETA-R, G protein-coupled receptor, hET-AR
Uniprot ID
Mouse ortholog
Ednra (13617)
endothelin-1 receptor (Q91VV2)
Alternate
EDNRB
EDNRB
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 1,179 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
165 adverse events reported
View more details
Premium feature
Learn more about premium features at pharmakb.com
Learn more